Trial Profile
MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MONARCC
- 18 Aug 2021 Trial design published in the BMC Cancer.
- 20 Jan 2021 Planned End Date changed from 1 Jun 2021 to 1 Sep 2022.
- 25 Jan 2020 Trial design results presented at the 2020 Gastrointestinal Cancers Symposium.